◎ Sugi Atlas

Atlas / Gene / NCAN

NCAN

gene
On this page

Summary

NCAN (neurocan, HGNC:2465) is a protein-coding gene on chromosome 19p12, encoding Neurocan core protein (O14594). May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM).

Neurocan is a chondroitin sulfate proteoglycan thought to be involved in the modulation of cell adhesion and migration.

Source: NCBI Gene 1463 — RefSeq curated summary.

At a glance

  • GWAS associations: 27
  • Clinical variants (ClinVar): 220 total
  • MANE Select transcript: NM_004386

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:2465
Approved symbolNCAN
Nameneurocan
Location19p12
Locus typegene with protein product
StatusApproved
Ensembl geneENSG00000130287
Ensembl biotypeprotein_coding
OMIM600826
Entrez1463

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 retained_intron

ENST00000252575, ENST00000585410, ENST00000588231, ENST00000590187, ENST00000910089, ENST00000910090, ENST00000910091, ENST00000927540, ENST00000952495, ENST00000952496

RefSeq mRNA: 1 — MANE Select: NM_004386 NM_004386

CCDS: CCDS12397

Canonical transcript exons

ENST00000252575 — 15 exons

ExonStartEnd
ENSE000008946431923825319238411
ENSE000008946471922648619227073
ENSE000008946481922497719225270
ENSE000008946491922430619224433
ENSE000008946501922402119224195
ENSE000008946511921891519219316
ENSE000008946521921694719217026
ENSE000027101811921195819212064
ENSE000029263131924976619252233
ENSE000034635671922728119228639
ENSE000034690681923378919233905
ENSE000036334551923498319235096
ENSE000036858671924870019248882
ENSE000037037811924531319245457
ENSE000037099251924060319240685

Expression profiles

Bgee: expression breadth ubiquitous, 126 present calls, max score 99.29.

FANTOM5 (CAGE): breadth broad, TPM avg 3.9049 / max 304.5395, expressed in 237 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter IDTPM avgSamples expressed
1747753.7371232
1747760.123276
2087400.044622

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
ventricular zoneUBERON:000305399.29gold quality
ganglionic eminenceUBERON:000402398.80gold quality
cortical plateUBERON:000534398.76gold quality
postcentral gyrusUBERON:000258196.38gold quality
CA1 field of hippocampusUBERON:000388196.38gold quality
parietal lobeUBERON:000187296.21gold quality
superior frontal gyrusUBERON:000266195.57gold quality
middle frontal gyrusUBERON:000270295.48gold quality
entorhinal cortexUBERON:000272894.66gold quality
Brodmann (1909) area 46UBERON:000648394.14gold quality
frontal poleUBERON:000279593.67gold quality
temporal lobeUBERON:000187193.61gold quality
Brodmann (1909) area 10UBERON:001354193.29gold quality
frontal cortexUBERON:000187093.11gold quality
neocortexUBERON:000195093.06gold quality
cerebral cortexUBERON:000095693.04gold quality
Brodmann (1909) area 9UBERON:001354093.00gold quality
nucleus accumbensUBERON:000188292.83gold quality
telencephalonUBERON:000189392.83gold quality
amygdalaUBERON:000187692.78gold quality
dorsolateral prefrontal cortexUBERON:000983492.73gold quality
occipital lobeUBERON:000202192.71gold quality
prefrontal cortexUBERON:000045192.69gold quality
caudate nucleusUBERON:000187392.61gold quality
orbitofrontal cortexUBERON:000416792.55gold quality
Ammon’s hornUBERON:000195492.35gold quality
right frontal lobeUBERON:000281092.32gold quality
cingulate cortexUBERON:000302792.15gold quality
putamenUBERON:000187492.12gold quality
paraflocculusUBERON:000535192.12gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-GEOD-84465yes12.35
E-ANND-3yes4.42

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EGR1

miRNA regulators (miRDB)

134 targeting NCAN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-6867-5P100.0082.213464
HSA-MIR-4795-3P100.0074.624024
HSA-MIR-126-5P100.0072.713180
HSA-MIR-6873-3P100.0071.422626
HSA-MIR-4283100.0066.422097
HSA-MIR-453499.9966.581907
HSA-MIR-428299.9975.366408
HSA-MIR-366299.9973.825684
HSA-MIR-6870-5P99.9968.552115
HSA-MIR-10401-5P99.9965.79948
HSA-MIR-520D-5P99.9873.344883
HSA-MIR-524-5P99.9873.434882
HSA-MIR-4723-5P99.9768.702034
HSA-MIR-569899.9768.492029
HSA-MIR-7111-5P99.9768.482062
HSA-MIR-493-5P99.9672.472382
HSA-LET-7C-3P99.9573.422862
HSA-MIR-808299.9567.271170
HSA-MIR-128-3P99.9571.172484
HSA-MIR-216A-3P99.9571.192505
HSA-MIR-452599.9464.38675
HSA-MIR-5010-5P99.9464.11705
HSA-MIR-218-5P99.9372.222103
HSA-MIR-6721-5P99.9368.922981
HSA-MIR-345-3P99.8970.231421
HSA-MIR-990299.8969.152250
HSA-MIR-3681-3P99.8870.462254
HSA-MIR-797899.8666.90856
HSA-MIR-3151-5P99.8663.831069
HSA-MIR-444799.8567.812900

Literature-anchored findings (GeneRIF, showing 15)

  • Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with bipolar disorder. (PMID:21353194)
  • High neurocan is associated with the invasive phenotype of low-grade astrocytoma. (PMID:21997179)
  • Sex (male)-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels is observed both the Mulao and Han ethnic groups. (PMID:22208664)
  • The rs1064395 A-allele was significantly over-represented in schizophrenia patients compared to controls. Our data suggest that genetic variation in NCAN is a common risk factor for bipolar disorder and schizophrenia. (PMID:22497794)
  • In the combined patient sample, the NCAN risk allele was significantly associated with the “mania” factor, in particular the subdimension “overactivity. (PMID:22952076)
  • no genetic association between risk allele A for NCAN locus rs1064395 and schizophrenia. (PMID:23198940)
  • NCAN rs2228603[T] is a risk factor for liver inflammation and fibrosis, suggesting that this locus is responsible for progression from steatosis to steatohepatitis. (PMID:23594525)
  • NCAN risk variant is associated with cortical folding and thickness in bipolar disorder and schizophrenia. (PMID:23795679)
  • The frequency of the NCAN rs2228603 T allele was significantly increased in patients with HCC due to ALD (15.1%) compared to alcoholic cirrhosis without HCC (9.3%), alcoholic controls (7.2%), healthy controls (7.9%), and HCV associated HCC (9.1%). (PMID:24946282)
  • Conditional analysis shows that a neighbouring gene, TM6SF2, not NCAN, is responsible for the Chr 19 GWAS locus previously associated with fibrosing non-alcoholic fatty liver disease (NAFLD). (PMID:24978903)
  • current data demonstrate that common genetic variation in NCAN influences both neural processing and cognitive performance in healthy subjects. (PMID:25220293)
  • NCAN genotype is associated with limbic gray matter alterations in healthy and subjects with major depression in brain areas implicated in emotion perception and regulation (PMID:25801500)
  • This study aims to analyze the influences of single-nucleotide polymorphism in the NCAN-CILP2 region on non-alcoholic fatty liver disease and plasma lipid levels in the Asian and Pacific ethnic groups. (PMID:26758378)
  • NCAN rs2228603 is not a risk factor for the incidence of NAFLD in Chinese population. The dual and opposite role of T variant in protecting liver with a higher level of HDL was found. (PMID:27887608)
  • Neurocan genome-wide psychiatric risk variant affects explicit memory performance and hippocampal function in healthy humans. (PMID:32583466)

Cross-species orthologs

4 orthologs

OrganismSymbolGene ID
danio_rerioncanbENSDARG00000005783
danio_rerioncanaENSDARG00000100128
mus_musculusNcanENSMUSG00000002341
rattus_norvegicusNcanENSRNOG00000048036

Paralogs (7): VCAN (ENSG00000038427), BCAN (ENSG00000132692), HAPLN2 (ENSG00000132702), HAPLN3 (ENSG00000140511), HAPLN1 (ENSG00000145681), ACAN (ENSG00000157766), HAPLN4 (ENSG00000187664)

Protein

Protein identifiers

Neurocan core protein — O14594 (reviewed: O14594)

Alternative names: Chondroitin sulfate proteoglycan 3

All UniProt accessions (2): O14594, K7EKF8

UniProt curated annotations — full annotation on UniProt →

Function. May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM). Chondroitin sulfate proteoglycan; binds to hyaluronic acid.

Subcellular location. Secreted.

Tissue specificity. Detected in cerebrospinal fluid (at protein level). Brain.

Post-translational modifications. O-glycosylated; contains chondroitin sulfate.

Similarity. Belongs to the aggrecan/versican proteoglycan family.

RefSeq proteins (1): NP_004377* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR000152EGF-type_Asp/Asn_hydroxyl_sitePTM
IPR000436Sushi_SCR_CCP_domDomain
IPR000538Link_domDomain
IPR000742EGFDomain
IPR001304C-type_lectin-likeDomain
IPR001881EGF-like_Ca-bd_domDomain
IPR003599Ig_subDomain
IPR007110Ig-like_domDomain
IPR013106Ig_V-setDomain
IPR013783Ig-like_foldHomologous_superfamily
IPR016186C-type_lectin-like/link_sfHomologous_superfamily
IPR016187CTDL_foldHomologous_superfamily
IPR018097EGF_Ca-bd_CSConserved_site
IPR018378C-type_lectin_CSConserved_site
IPR035976Sushi/SCR/CCP_sfHomologous_superfamily
IPR036179Ig-like_dom_sfHomologous_superfamily
IPR050691Hyaluronan_bind_ProteoglycanFamily

Pfam: PF00008, PF00059, PF00084, PF00193, PF07686

UniProt features (51 total): disulfide bond 16, region of interest 9, domain 7, compositionally biased region 6, glycosylation site 6, sequence variant 3, sequence conflict 2, signal peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-O14594-F158.750.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (16): 59–140, 182–253, 206–227, 280–355, 304–325, 1012–1023, 1017–1032, 1034–1043, 1050–1061, 1055–1070, 1072–1081, 1088–1099, 1116–1208, 1184–1200, 1215–1258, 1244–1271

Glycosylation sites (6): 122, 340, 381, 411, 1026, 1223

Function

Pathways and Gene Ontology

Reactome pathways

27 pathways

IDPathway
R-HSA-1971475Glycosaminoglycan-protein linkage region biosynthesis
R-HSA-2022870CS-GAG biosynthesis
R-HSA-2022923DS-GAG biosynthesis
R-HSA-2024101CS/DS degradation
R-HSA-3000178ECM proteoglycans
R-HSA-3560783Defective B4GALT7 causes EDS, progeroid type
R-HSA-3560801Defective B3GAT3 causes JDSSDHD
R-HSA-3595172Defective CHST3 causes SEDCJD
R-HSA-3595174Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595177Defective CHSY1 causes TPBS
R-HSA-373760L1CAM interactions
R-HSA-419037NCAM1 interactions
R-HSA-4420332Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-1266738Developmental Biology
R-HSA-1430728Metabolism
R-HSA-1474244Extracellular matrix organization
R-HSA-1630316Glycosaminoglycan metabolism
R-HSA-1638091Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1643685Disease
R-HSA-1793185Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-3560782Diseases associated with glycosaminoglycan metabolism
R-HSA-375165NCAM signaling for neurite out-growth
R-HSA-3781865Diseases of glycosylation
R-HSA-422475Axon guidance
R-HSA-5668914Diseases of metabolism
R-HSA-71387Metabolism of carbohydrates and carbohydrate derivatives
R-HSA-9675108Nervous system development

MSigDB gene sets: 170 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, GSE45365_NK_CELL_VS_CD11B_DC_UP, GNF2_RTN1, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, MEF2_02, MODULE_66, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6, MODULE_410, TGANTCA_AP1_C

GO Biological Process (3): skeletal system development (GO:0001501), cell adhesion (GO:0007155), central nervous system development (GO:0007417)

GO Molecular Function (3): calcium ion binding (GO:0005509), hyaluronic acid binding (GO:0005540), carbohydrate binding (GO:0030246)

GO Cellular Component (6): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), Golgi lumen (GO:0005796), lysosomal lumen (GO:0043202), synapse (GO:0045202), perineuronal net (GO:0072534)

Reactome top-level categories

Rollup of top-7 pathways:

CategoryPathways
Diseases associated with glycosaminoglycan metabolism6
Glycosaminoglycan metabolism3
Chondroitin sulfate/dermatan sulfate metabolism3
Extracellular matrix organization1
Axon guidance1
NCAM signaling for neurite out-growth1
Metabolism of carbohydrates and carbohydrate derivatives1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
system development2
cellular process1
nervous system development1
metal ion binding1
carboxylic acid binding1
binding1
cellular anatomical structure1
Golgi apparatus1
intracellular organelle lumen1
lysosome1
vacuolar lumen1
cell junction1
perisynaptic extracellular matrix1

Protein interactions and networks

STRING

2012 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
NCANPTPRZ1P23471972
NCANACANP16112949
NCANVCANP13611946
NCANBCANQ96GW7908
NCANPNPLA3Q9NST1750
NCANMEF2BQ02080746
NCANTM6SF2Q9BZW4743
NCANRFXANKO14593742
NCANLYPLAL1Q5VWZ2696
NCANPPP1R3BQ86XI6662
NCANGPC1P35052628
NCANCILP2Q8IUL8581
NCANTENM4Q6N022571
NCANAXLP30530550
NCANTYRO3Q06418550

IntAct

4 interactions, top by confidence:

ABTypeScore
NCANpsi-mi:“MI:0915”(physical association)0.370
MAPTNCANpsi-mi:“MI:0914”(association)0.350
APPESYT2psi-mi:“MI:0914”(association)0.350

BioGRID (15): NCAN (Reconstituted Complex), NCAN (Far Western), NCAN (Reconstituted Complex), NCAN (Reconstituted Complex), NCAN (Reconstituted Complex), NCAN (Affinity Capture-Western), NCAN (Reconstituted Complex), NCAN (Co-fractionation), LIG1 (Co-fractionation), MNAT1 (Co-fractionation), KTN1 (Co-fractionation), CMTR1 (Co-fractionation), NCAN (Cross-Linking-MS (XL-MS)), MTRR (Cross-Linking-MS (XL-MS)), NCAN (Affinity Capture-MS)

ESM2 similar proteins: A0A2R8Y7Y5, A1KXC4, A6QLF8, C9JL84, E9Q7X6, I3L273, J3KML8, O00592, O14594, O35188, O55145, O57604, O60667, O95196, P06484, P07141, P09603, P13838, P15702, P16150, P55067, P59647, P78423, Q1ECS6, Q28645, Q2TA21, Q2TB54, Q3TNW5, Q3TYV2, Q4V7A5, Q52S86, Q58Y74, Q5IS41, Q5M871, Q5SWP3, Q6MG22, Q6NXZ1, Q6UXF1, Q71M36, Q7Z434

Diamond homologs: A5PMY6, A6QP79, D3ZWT9, O14594, P02706, P02707, P05451, P06734, P07306, P07307, P07897, P07898, P08290, P08661, P10716, P10758, P11226, P13608, P13611, P16112, P19999, P20693, P22897, P24721, P34927, P41317, P43137, P48304, P49300, P49301, P55066, P55067, P60883, P70194, P81282, P82596, P86854, Q28343, Q28670, Q29011

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

220 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance197
Likely benign12
Benign3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2358 predictions. Top by Δscore:

VariantEffectΔscore
19:19213464:GAGC:Gdonor_gain1.0000
19:19217025:GG:Gdonor_gain1.0000
19:19217026:GG:Gdonor_gain1.0000
19:19219314:CAG:Cdonor_loss1.0000
19:19219315:AGGTC:Adonor_loss1.0000
19:19219317:G:Cdonor_loss1.0000
19:19224016:CACA:Cacceptor_loss1.0000
19:19224018:CAGGT:Cacceptor_loss1.0000
19:19224020:GGT:Gacceptor_gain1.0000
19:19224020:GGTGT:Gacceptor_gain1.0000
19:19224146:G:GTdonor_gain1.0000
19:19224165:A:AGdonor_gain1.0000
19:19224191:GTTCG:Gdonor_gain1.0000
19:19224302:TCA:Tacceptor_loss1.0000
19:19224303:CAGGT:Cacceptor_loss1.0000
19:19224305:GGT:Gacceptor_gain1.0000
19:19224394:G:GTdonor_gain1.0000
19:19224429:GGGGG:Gdonor_gain1.0000
19:19224430:GGGG:Gdonor_gain1.0000
19:19224430:GGGGG:Gdonor_gain1.0000
19:19224431:GGG:Gdonor_gain1.0000
19:19224431:GGGG:Gdonor_gain1.0000
19:19224432:GGG:Gdonor_gain1.0000
19:19225271:G:GAdonor_loss1.0000
19:19225272:T:Adonor_loss1.0000
19:19226481:CACA:Cacceptor_loss1.0000
19:19226482:ACAG:Aacceptor_loss1.0000
19:19226483:CA:Cacceptor_loss1.0000
19:19226484:A:AGacceptor_gain1.0000
19:19226484:A:Cacceptor_loss1.0000

AlphaMissense

8592 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
19:19224173:T:AW210R1.000
19:19224173:T:CW210R1.000
19:19224175:G:CW210C1.000
19:19224175:G:TW210C1.000
19:19238329:G:CW1109C1.000
19:19238329:G:TW1109C1.000
19:19240667:G:CW1158C1.000
19:19240667:G:TW1158C1.000
19:19245405:G:CW1195C1.000
19:19245405:G:TW1195C1.000
19:19219073:T:AW78R0.999
19:19219073:T:CW78R0.999
19:19219075:G:CW78C0.999
19:19219075:G:TW78C0.999
19:19224090:G:AC182Y0.999
19:19224091:C:GC182W0.999
19:19224129:T:CL195P0.999
19:19224161:T:AC206S0.999
19:19224161:T:CC206R0.999
19:19224162:G:AC206Y0.999
19:19224162:G:CC206S0.999
19:19224162:G:TC206F0.999
19:19224163:T:GC206W0.999
19:19224177:T:CL211P0.999
19:19224334:T:AC227S0.999
19:19224334:T:CC227R0.999
19:19224335:G:CC227S0.999
19:19224404:A:TD250V0.999
19:19224414:C:GC253W0.999
19:19225089:G:CW297C0.999

dbSNP variants (sampled 300 via entrez): RS1000003668 (19:19224827 C>G,T), RS1000047324 (19:19214450 G>T), RS1000189112 (19:19218828 TA>T,TAA), RS1000225425 (19:19250084 A>G), RS1000236719 (19:19225379 T>A), RS1000260102 (19:19212838 A>G,T), RS1000288272 (19:19231970 A>G), RS1000289637 (19:19213052 G>A,T), RS1000346913 (19:19246899 G>A), RS1000560999 (19:19218636 C>G), RS1000587004 (19:19225765 C>T), RS1000614581 (19:19243256 G>A), RS1000641519 (19:19213220 G>T), RS1000650841 (19:19224951 C>A,G,T), RS1000707424 (19:19235586 T>TTA)

Disease associations

OMIM: gene MIM:600826 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

27 associations (top):

StudyTraitp-value
GCST000132_3LDL cholesterol3.000000e-09
GCST000139_9Triglycerides3.000000e-09
GCST000282_3LDL cholesterol3.000000e-06
GCST000285_13Cholesterol, total2.000000e-15
GCST000286_11Triglycerides4.000000e-11
GCST000287_4LDL cholesterol2.000000e-08
GCST000289_5Triglycerides3.000000e-06
GCST000758_7Triglycerides2.000000e-29
GCST000759_15LDL cholesterol7.000000e-22
GCST000760_8Cholesterol, total3.000000e-38
GCST000985_1Bipolar disorder2.000000e-09
GCST002149_11Schizophrenia3.000000e-09
GCST002385_2Bipolar disorder9.000000e-08
GCST002539_89Schizophrenia4.000000e-10
GCST003302_4Cholesterol, total1.000000e-13
GCST003303_3LDL cholesterol2.000000e-08
GCST003678_5C-reactive protein levels or total cholesterol levels (pleiotropy)1.000000e-35
GCST003679_18C-reactive protein levels or LDL-cholesterol levels (pleiotropy)7.000000e-21
GCST005308_7Nonalcoholic fatty liver disease2.000000e-08
GCST006803_88Schizophrenia7.000000e-12
GCST008103_10Bipolar disorder1.000000e-09
GCST008115_2Bipolar I disorder3.000000e-09
GCST008116_4Bipolar II disorder4.000000e-06
GCST010002_52Refractive error4.000000e-29
GCST010703_335Brain morphology (MOSTest)3.000000e-10
GCST011102_22Bipolar disorder5.000000e-10
GCST90002400_276Plateletcrit4.000000e-09

EFO canonical traits (8, from GWAS)

EFO IDTrait name
EFO:0004611low density lipoprotein cholesterol measurement
EFO:0004530triglyceride measurement
EFO:0004574total cholesterol measurement
EFO:0004458C-reactive protein measurement
EFO:0009963bipolar I disorder
EFO:0009964bipolar II disorder
EFO:0004346neuroimaging measurement
EFO:0007985platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

ChemicalActions (top 5)PubMed papers
Valproic Acidaffects cotreatment, decreases expression, affects expression, increases expression6
trichostatin Adecreases expression, affects cotreatment3
mercuric bromidedecreases expression, affects cotreatment2
Benzo(a)pyreneaffects methylation, decreases expression, increases methylation2
Phenylmercuric Acetateaffects cotreatment, decreases expression2
p-Chloromercuribenzoic Acidaffects cotreatment, decreases expression2
methylmercuric chloridedecreases expression1
methyleugenoldecreases expression1
azoxystrobindecreases expression1
deguelindecreases expression1
fenpyroximatedecreases expression1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamidedecreases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, decreases expression1
pyrimidifendecreases expression1
belinostatdecreases expression1
thifluzamidedecreases expression1
abrineincreases expression1
pyrachlostrobindecreases expression1
dorsomorphinaffects cotreatment, decreases expression1
picoxystrobindecreases expression1
Antimycin Adecreases expression1
Arsenicincreases methylation1
Arsenicalsincreases methylation1
Phenytoinincreases expression1
Potassium Dichromateincreases expression1
Rotenonedecreases expression1
Tretinoindecreases expression1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 75

This page pulls from 75 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot